小细胞肺癌中的新型细胞毒性化疗药物
Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma.
作者信息
Cortinovis Diego, Bidoli Paolo, Canova Stefania, Colonese Francesca, Gemelli Maria, Lavitrano Maria Luisa, Banna Giuseppe Luigi, Liu Stephen V, Morabito Alessandro
机构信息
Department Medical Oncology-ASST-Monza Ospedale San Gerardo, via Pergolesi 33, 20090 Monza, Italy.
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
出版信息
Cancers (Basel). 2021 Mar 8;13(5):1152. doi: 10.3390/cancers13051152.
Abstract
Small cell lung cancer (SCLC) is one of the deadliest thoracic neoplasms, in part due to its fast doubling time and early metastatic spread. Historically, cytotoxic chemotherapy consisting of platinum-etoposide or anthracycline-based regimens has demonstrated a high response rate, but early chemoresistance leads to a poor prognosis in advanced SCLC. Only a fraction of patients with limited-disease can be cured by chemo-radiotherapy. Given the disappointing survival rates in advanced SCLC, new cytotoxic agents are eagerly awaited. Unfortunately, few novel chemotherapy drugs have been developed in the latest decades. This review describes the results and potential application in the clinical practice of novel chemotherapy agents for SCLC.
摘要
小细胞肺癌（SCLC）是最致命的胸部肿瘤之一，部分原因是其快速的倍增时间和早期转移扩散。从历史上看，由铂类-依托泊苷或蒽环类药物组成的细胞毒性化疗方案已显示出较高的缓解率，但早期化疗耐药导致晚期SCLC的预后较差。只有一小部分局限性疾病患者可以通过放化疗治愈。鉴于晚期SCLC令人失望的生存率，人们急切期待新的细胞毒性药物。不幸的是，近几十年来几乎没有开发出新的化疗药物。本综述描述了用于SCLC的新型化疗药物的研究结果及其在临床实践中的潜在应用。
相似文献
1
Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma.小细胞肺癌中的新型细胞毒性化疗药物
Cancers (Basel). 2021 Mar 8;13(5):1152. doi: 10.3390/cancers13051152.
2
Update 2021: Management of Small Cell Lung Cancer.更新于 2021 年：小细胞肺癌的治疗。
Lung. 2021 Dec;199(6):579-587. doi: 10.1007/s00408-021-00486-y. Epub 2021 Nov 10.
3
Current standards of care in small-cell and non-small-cell lung cancer.小细胞肺癌和非小细胞肺癌的当前护理标准。
Oncology. 2001;61 Suppl 1:3-13. doi: 10.1159/000055386.
4
Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.小细胞肺癌（局限期和广泛期）的初始治疗及胸放疗和一线化疗的作用：系统评价。
Curr Oncol. 2019 Jun;26(3):e372-e384. doi: 10.3747/co.26.4481. Epub 2019 Jun 1.
5
Drugs in development for small cell lung cancer.正在研发用于小细胞肺癌的药物。
J Thorac Dis. 2020 Oct;12(10):6298-6307. doi: 10.21037/jtd-2019-sclc-10.
6
Lurbinectedin for the treatment of small cell lung cancer.鲁比卡丁治疗小细胞肺癌。
Drugs Today (Barc). 2021 Jun;57(6):377-385. doi: 10.1358/dot.2021.57.6.3294559.
7
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.100例小细胞肺癌患者使用标准剂量和高剂量依托泊苷、异环磷酰胺、卡铂及表柔比星的研究：一项成熟的随访报告
Ann Oncol. 1999 May;10(5):561-7. doi: 10.1023/a:1026453922931.
8
Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy.免疫治疗时代之前真实世界证据ESME队列中广泛期小细胞肺癌（SCLC）的治疗模式和临床结局
Respir Med Res. 2023 Nov;84:101012. doi: 10.1016/j.resmer.2023.101012. Epub 2023 Mar 27.
9
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions.小细胞肺癌的临床洞察：肿瘤异质性、诊断、治疗和未来方向。
CA Cancer J Clin. 2023 Nov-Dec;73(6):620-652. doi: 10.3322/caac.21785. Epub 2023 Jun 17.
10
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.接受铂类/依托泊苷再挑战治疗的铂敏感小细胞肺癌患者的结局：一项多机构回顾性分析
Clin Lung Cancer. 2015 Nov;16(6):e223-8. doi: 10.1016/j.cllc.2015.04.006. Epub 2015 Apr 24.
引用本文的文献
1
Novel strategy for comprehensive therapy with sustainably complete response in a patient with limited-stage small cell lung cancer: a case report.局限期小细胞肺癌患者综合治疗并持续完全缓解的新策略：一例病例报告
J Int Med Res. 2024 Dec;52(12):3000605241305429. doi: 10.1177/03000605241305429.
2
Oncogenic alterations in advanced NSCLC: a molecular super-highway.晚期非小细胞肺癌中的致癌改变：一条分子高速公路。
Biomark Res. 2024 Feb 12;12(1):24. doi: 10.1186/s40364-024-00566-0.
3
A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection.一种基于15个基因的风险特征用于预测接受手术切除的小细胞肺癌患者的总生存期。
Cancers (Basel). 2023 Oct 30;15(21):5219. doi: 10.3390/cancers15215219.
4
Effect of the isotiazole adjuvants in combination with cisplatin in chemotherapy of neuroepithelial tumors: experimental results and modeling.异噻唑增效剂联合顺铂化疗神经上皮肿瘤的效果：实验结果与建模。
Sci Rep. 2023 Aug 21;13(1):13624. doi: 10.1038/s41598-023-40094-9.
5
Risk factors of early mortality in patients with small cell lung cancer: a retrospective study in the SEER database.小细胞肺癌患者早期死亡的风险因素：SEER 数据库中的回顾性研究。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11193-11205. doi: 10.1007/s00432-023-05003-7. Epub 2023 Jun 24.
6
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC).2022年广泛期小细胞肺癌（SCLC）最新进展
J Cancer. 2022 Jul 18;13(9):2945-2953. doi: 10.7150/jca.75622. eCollection 2022.
7
First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy.晚期小细胞肺癌的一线治疗：化疗免疫疗法之外还有什么。
Front Med (Lausanne). 2022 May 25;9:924853. doi: 10.3389/fmed.2022.924853. eCollection 2022.
8
Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.ASCL1 和 NEUROD1 依赖性基因的启动子是 lurbinectedin 在 SCLC 细胞中的特异性靶标。
EMBO Mol Med. 2022 Apr 7;14(4):e14841. doi: 10.15252/emmm.202114841. Epub 2022 Mar 9.
9
Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?基于脂质的纳米颗粒在推进抗癌生物碱的临床转化方面有前景吗？
Cancers (Basel). 2021 Oct 25;13(21):5346. doi: 10.3390/cancers13215346.
10
Small Cell Lung Cancer: A New Era Is Beginning?小细胞肺癌：一个新时代即将开启？
Cancers (Basel). 2021 May 28;13(11):2646. doi: 10.3390/cancers13112646.
本文引用的文献
1
First-line immune-checkpoint inhibitor plus chemotherapy chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis.一线免疫检查点抑制剂联合化疗与单纯化疗治疗广泛期小细胞肺癌的Meta分析
Ther Adv Med Oncol. 2020 Dec 9;12:1758835920977137. doi: 10.1177/1758835920977137. eCollection 2020.
2
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合或不联合 Tremelimumab 与单用依托泊苷联合顺铂一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、3 期临床试验的更新结果。
Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4.
3
A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.一项比较贝洛替康单药与拓扑替康单药治疗敏感复发性小细胞肺癌的疗效和安全性的随机 2b 期研究。
Br J Cancer. 2021 Feb;124(4):713-720. doi: 10.1038/s41416-020-01055-5. Epub 2020 Nov 16.
4
The rediscovery of platinum-based cancer therapy.铂类抗癌疗法的再发现。
Nat Rev Cancer. 2021 Jan;21(1):37-50. doi: 10.1038/s41568-020-00308-y. Epub 2020 Oct 30.
5
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.来那替尼在适合重新使用一线治疗药物进行再挑战的二线小细胞肺癌患者中的抗肿瘤活性。
Lung Cancer. 2020 Dec;150:90-96. doi: 10.1016/j.lungcan.2020.10.003. Epub 2020 Oct 10.
6
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials.将程序性死亡蛋白1/程序性死亡配体1（PD-1/PD-L1）抑制剂添加至化疗用于广泛期小细胞肺癌（SCLC）一线治疗的随机试验荟萃分析
Cancers (Basel). 2020 Sep 16;12(9):2645. doi: 10.3390/cancers12092645.
7
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.卡铂联合依托泊苷与拓扑替康二线治疗敏感复发性小细胞肺癌的疗效比较：一项开放标签、多中心、随机、III 期临床试验。
Lancet Oncol. 2020 Sep;21(9):1224-1233. doi: 10.1016/S1470-2045(20)30461-7.
8
Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.延长生存：免疫检查点抑制剂在广泛期小细胞肺癌治疗中的作用。
Oncologist. 2020 Nov;25(11):981-992. doi: 10.1634/theoncologist.2020-0193. Epub 2020 Sep 23.
9
Comparison of oral versus intravenous etoposide in the management of small-cell lung cancer; A real-world, population-based study.口服依托泊苷与静脉依托泊苷治疗小细胞肺癌的比较；一项真实世界、基于人群的研究。
Clin Respir J. 2021 Jan;15(1):36-41. doi: 10.1111/crj.13266. Epub 2020 Sep 7.
10
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.《COVID-19 大流行期间的癌症患者管理：ESMO 多学科专家共识》
Ann Oncol. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. Epub 2020 Jul 31.
Zotero 插件